Analyst Comment Second Alzheimer’s drug rejected by NICE on the same day it is approved in the UK Kisunla's approval was based on data from the Phase III TRAILBLAZER-ALZ 2 trial. GlobalData Healthcare
Analyst Comment Oral GLP-1 receptor agonist Rybelsus reduces risk of cardiovascular events in type 2 diabetes patients
Analyst Comment AAO 2024: Neurodegeneration marker apolipoprotein E is elevated in the serum of patients with glaucoma
Analyst Comment AAO 2024: Phase II study on the safety of intravitreal NT-501 encapsulated cell therapy implantation for glaucoma treatment
Analyst Comment IDWeek 2024: Prevention and treatment for HIV – clinical trials and policy challenges
Analyst Comment IDWeek 2024: Moderna’s norovirus vaccine mRNA-1403 shows potential in Phase I/II trial GlobalData Healthcare
Analyst Comment Sepsis deaths are still high, with 50% mortality within two years GlobalData Healthcare
Analyst Comment AAO 2024: Rezolute’s RZ-402 shows promising Phase IIa results in DME patients GlobalData Healthcare
Analyst Comment Results of Phase I trial shed positive light on UNI-494 for acute kidney injury GlobalData Healthcare
Analyst Comment Lebrikizumab, tralokinumab and dupilumab to compete in atopic dermatitis space GlobalData Healthcare
Analyst Comment Women are dying unnecessarily due to the underdiagnosis of heart disease GlobalData Healthcare
Analyst Comment Crucial drug shortages questions the exclusion of pregnant women in clinical trials GlobalData Healthcare
Analyst Comment Mpox declared international public health emergency as cases continue to rise GlobalData Healthcare
Analyst Comment US’ first self-administered flu vaccine could increase accessibility and uptake GlobalData Healthcare
Analyst Comment As GSK discontinues HSV vaccine, opportunities remain for Moderna and BioNTech GlobalData Healthcare
Analyst Comment ESMO 2024: Can Jiangsu Hengrui Pharma disrupt the HER2-mGEJ treatment paradigm? GlobalData Healthcare
Analyst Comment Uncontrolled antimicrobial use causes rise in deaths due to superbugs GlobalData Healthcare
Analyst Comment Keytruda keys in on survival: Promising results in high-risk early-stage TNBC from KEYNOTE-522 GlobalData Healthcare
Analyst Comment ESMO 2024: Anlotinib and penpulimab – to the Moon and beyond for advanced HCC? GlobalData Healthcare
Analyst Comment ESMO 2024: Eli Lilly brings the competition to Novartis with new results in mCRPC GlobalData Healthcare
Analyst Comment ESMO-2024: Enhertu to eclipse the standard of care in HER2+ breast cancer with brain metastases GlobalData Healthcare
Analyst Comment ESMO 2024: Imfinzi to be practice changing in perioperative bladder cancer setting GlobalData Healthcare
Analyst Comment ESMO 2024: TROP2-directed ADCs show promise in recurrent gynecological cancers GlobalData Healthcare
Analyst Comment ESMO 2024: Anlotinib and penpulimab gather attention in HCC with APOLLO results GlobalData Healthcare
Analyst Comment ESMO 2024: Enhertu to eclipse SOC for HER2+ breast cancer with brain metastases GlobalData Healthcare
Analyst Comment ESMO 2024: Tecentriq/Avastin’s prospects as the first HCC adjuvant therapy fade GlobalData Healthcare